<DOC>
	<DOC>NCT01648764</DOC>
	<brief_summary>The purpose of this study is to evaluate two different dosing regimens of LY2334737 in participants with cancer that is advanced and/or has spread to other parts of the body. Information about side effects will be collected.</brief_summary>
	<brief_title>A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread</brief_title>
	<detailed_description>This study will consist of a Dose Escalation Phase (Arms A and B) followed by a Dose Confirmation Phase.</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Deoxyuridine</mesh_term>
	<criteria>Diagnosis of advanced and/or metastatic cancer (including lymphoma) for which no treatment of higher priority exists Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 2 Estimated life expectancy of more than 12 weeks Have discontinued all previous therapies for cancer for at least 30 days (6 weeks for mitomycinC or nitrosoureas) and recovered from acute effects of therapy Have discontinued radiotherapy more than one week before enrolling in the study and have recovered from the acute affects of therapy Have adequate organ function Follow your doctor's directions and live close enough to the study site so you can continue to go to the clinic for followup Are willing and able to swallow capsules and follow study procedures Have given written informed consent prior to any studyspecific procedures Males and females with reproductive potential should use medically approved contraceptive precautions during the study and for 6 months following the last dose of study drug Females with childbearing potential must have had a negative urine or serum pregnancy test 7 days prior to the first dose of study drug Have gastrointestinal diseases or prior surgery that may interfere with the absorption of medication taken by mouth Females who are pregnant or lactating Symptomatic central nervous system malignancy or metastasis Known positive test results in human immunodeficiency virus (HIV), hepatitis B surface antigen (HBSAg), or hepatitis C antibodies (HCAb) Liver cirrhoses or chronic hepatitis Acute or chronic leukemia Are currently receiving treatment with valproic acid (VPA) and it's derivatives, or if you have a history of intolerance to VPA Known hypersensitivity to gemcitabine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>